They've been aiming at the wrong part of the cell. For decades scientists zeroed in on Toll-like receptors as the linchpin of inflammatory disease. It made sense: these receptors spot danger, bind signaling proteins, and set off the immune response. But new work from Boston Children’s Hospital flips that script.
Published in Nature on September 23, 2026, the study follows a trail of molecular events that continues after receptors let go. The team observed that signaling proteins must first detach from Toll-like receptors before assembling into a distinct intracellular machine — the myddosome — that turns on inflammatory genes. Release, it turns out, is not the end of the message. It is a necessary step toward a second, receptor-free phase that keeps inflammation alive.
Think of it as a relay race. The receptor hands off the baton, then watches as a new runner — the myddosome — charges down the track and completes the course. Under the classic model, losing contact with the starter should halt the race. Here, that separation enables a different player to take over.
The discovery helps explain a stubborn puzzle: why therapies that target Toll-like receptors rarely produce lasting relief in autoimmune conditions. If inflammation continues downstream in a receptor-independent form, then blocking the receptor is like turning off a lighthouse while a fire burns inland. The Boston Children’s team found that myddosome assembly requires the proteins to be free from the receptor; tethered proteins can’t form the complex or activate the genes that sustain inflammation.
The myddosome itself may be a more practical drug target than the receptors that kick the process off.
Jonathan Kagan, PhD, the study’s senior author and director of basic research at Boston Children’s, describes the finding as an expansion of how we think about cellular signaling. The group didn’t stop at observation. In mouse experiments, pharmacological disruption of myddosome formation dampened inflammation, offering a proof-of-concept that interfering with the complex — rather than the receptor — can reverse disease signs.
That shift in strategy opens new avenues for drug discovery. Rather than hunting for molecules that blunt receptor activity, researchers could search for small compounds that prevent myddosome assembly or destabilize the complex once it forms. Such agents might be effective across a range of disorders where Toll-like receptor pathways are implicated, from autoimmune conditions to chronic inflammatory diseases.
Of course, translating a cellular insight into safe, effective medicines is a long road. The myddosome is woven into normal immune defenses, so any therapy will need to tamp down pathological inflammation without leaving patients defenseless. Still, this work offers a clearer map for the journey.
When the body’s alarms keep ringing even after the switch is flipped, sometimes the smartest move is to follow the wiring — not just silence the buzzer.
Leave a Comment
Comments
No comments yet. Be the first.